ClinicalTrials.gg
RecruitingNCT06727812Updated Dec 18, 2025

Multicenter Phase I Study of HRS-6208 in Patients With Solid Tumors

A Phase 1 interventional study of HRS-6208 in Solid Tumors, sponsored by Shandong Suncadia Medicine Co., Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-18.

Sponsored by Shandong Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
206
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is an open, multicenter Phase I study to evaluate the safety and tolerability of HRS-6208 in patients with advanced solid tumors.

02

Conditions studied

  • Solid Tumors
03

In context

Lead sponsor

Shandong Suncadia Medicine Co., Ltd. is the lead sponsor of 87 studies on the registry; 39 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with unresectable locally advanced or solid tumors confirmed by histology or cytology who have or progressed after standard treatment, or have no standard treatment options, or do not apply standard treatment at this stage;
  2. Age 18\~75 years old;
  3. At least one per v1.1 criteria;
  4. PS score: 0-1.

Exclusion criteria

Exclusion Criteria:

  1. History of other within the past 5 years, excluding cured basal cell carcinoma of the skin and carcinoma in situ of the cervix;
  2. The adverse reactions of previous anti-tumor therapy have not recovered to v5.0 grade evaluation ≤ 1;
  3. He has severe cardiovascular and cerebrovascular diseases;
  4. Severe infection within 4 weeks prior to the first dose.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
206 participants (estimated)

Study arms

  • Experimental
    Experimental arm

    Drug: HRS-6208

Interventions

  • DrugHRS-6208

    HRS-6208.

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events (AEs)

    Time frame: From Day 1 to 30 days after the last dose.

  2. Maximum tolerated dose (MTD)

    Time frame: From Day 1 to 21 days after the first dose.

  3. Dose limiting toxicity (DLT)

    Time frame: From Day 1 to 21 days after the first dose.

  4. Recommended phase 2 dose (RP2D)

    Time frame: From Day 1 to 30 days after the last dose.

Secondary outcomes

  1. Objective Response Rate (ORR)

    Time frame: From time of first dose of HRS-6208 until the date of objective disease progression or death (up to 24 months).

  2. Duration of Response (DoR)

    Time frame: From time of first dose of HRS-6208 until the date of objective disease progression or death (up to 24 months).

  3. Disease Control Rate (DCR)

    Time frame: From time of first dose of HRS-6208 until the date of objective disease progression or death (up to 24 months).

  4. Progression free Survival (PFS)

    Time frame: From time of first dose of HRS-6208 until the date of objective disease progression or death (up to 24 months).

  5. Overall Survival (OS)

    Time frame: From time of first dose of HRS-6208 until the date of objective disease progression or death (up to 24 months).

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Aug 2027, 32 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2024
First posted
Dec 11, 2024
StartActual
Dec 17, 2024
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2027
Last update
Dec 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06727812
Responsible party
Sponsor
First posted
Dec 11, 2024
Start date
Dec 17, 2024
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Dec 18, 2025

Study contacts

Xin Xu
Contact
xin.xu@hengrui.com
0518-82342973
Zhiye Chen
Contact
zhiye.chen.zc78@hengrui.com
0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion